Baron Partners Fund Highlights IDEXX’s 63.6% 2025 Gain and New Diagnostics
Baron Partners Fund’s Institutional Shares returned 19.07% in Q4 2025, beating the Russell Midcap Growth Index’s -3.70% and Russell 3000’s 2.40%, and achieved 24.86% for the calendar year. IDEXX Laboratories delivered a 63.6% stock surge in 2025, with -9.0% monthly and 41.36% annual returns on a $51.73 billion market capitalization.
1. Baron Partners Fund Performance
Baron Partners Fund’s Institutional Shares rose 19.07% in Q4 2025, outpacing the Russell Midcap Growth Index’s -3.70% and the Russell 3000’s 2.40%. The fund delivered a 24.86% return for 2025, highlighting its focus on long-term growth businesses at attractive valuations.
2. IDEXX Laboratories Financial Snapshot
IDEXX Laboratories holds a $51.73 billion market capitalization and reported a -9.0% return over the past month and 41.36% over the past twelve months. The stock surged 63.6% in 2025 on better-than-expected financial results and strong diagnostic test utilization.
3. New Diagnostic Innovations
IDEXX launched a new diagnostic test in 2025 and expects another in 2026, with utilization already exceeding expectations. Proprietary platforms such as InVue, MultiCue and CancerDX are expected to drive meaningful revenue contributions in the coming years.
4. Secular Pet Care Trends
Long-term secular trends in pet ownership and increased pet care spending have structurally accelerated, underpinning demand for IDEXX’s veterinary diagnostics. Baron Partners Fund cites these trends as key drivers of IDEXX’s sustainable growth trajectory.